Trevi Therapeutics' (TRVI) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI - Free Report) in a research report report published on Tuesday morning, Benzinga reports. The firm currently has a $6.00 price objective on the stock.

Other research analysts have also issued research reports about the stock. Leerink Partnrs raised shares of Trevi Therapeutics to a "strong-buy" rating in a research note on Monday, September 9th. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a "strong-buy" rating in a research note on Monday, August 19th. Raymond James started coverage on shares of Trevi Therapeutics in a research report on Friday, August 30th. They set an "outperform" rating and a $9.00 price target on the stock. Leerink Partners started coverage on shares of Trevi Therapeutics in a research report on Monday, September 9th. They set an "outperform" rating and a $7.00 price target on the stock. Finally, Needham & Company LLC reissued a "buy" rating and set a $8.00 price target on shares of Trevi Therapeutics in a research report on Friday, October 4th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Trevi Therapeutics currently has an average rating of "Buy" and a consensus target price of $7.43.

Trevi Therapeutics Stock Performance

Shares of NASDAQ TRVI traded down $0.12 during mid-day trading on Tuesday, reaching $3.23. The company's stock had a trading volume of 2,609,149 shares, compared to its average volume of 278,359. The stock has a 50-day moving average of $3.10 and a two-hundred day moving average of $2.89. The stock has a market capitalization of $227.51 million, a P/E ratio of -9.50 and a beta of 0.97. Trevi Therapeutics has a 1-year low of $0.97 and a 1-year high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.01). During the same quarter in the previous year, the firm earned ($0.07) EPS. Analysts predict that Trevi Therapeutics will post -0.47 EPS for the current fiscal year.

Insider Buying and Selling at Trevi Therapeutics

In other news, insider Thomas Sciascia sold 18,660 shares of the business's stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the completion of the sale, the insider now owns 220,315 shares in the company, valued at approximately $608,069.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Trevi Therapeutics news, CEO Jennifer L. Good sold 10,981 shares of the company's stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total value of $33,162.62. Following the transaction, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at $644,205.26. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Thomas Sciascia sold 18,660 shares of the company's stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $2.76, for a total value of $51,501.60. Following the completion of the transaction, the insider now directly owns 220,315 shares in the company, valued at approximately $608,069.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,355 shares of company stock worth $116,663 in the last 90 days. 24.37% of the stock is owned by company insiders.

Institutional Investors Weigh In On Trevi Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TRVI. American Century Companies Inc. increased its position in Trevi Therapeutics by 17.1% in the second quarter. American Century Companies Inc. now owns 54,108 shares of the company's stock worth $161,000 after buying an additional 7,902 shares during the period. The Manufacturers Life Insurance Company increased its position in Trevi Therapeutics by 87.6% in the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company's stock worth $73,000 after buying an additional 11,450 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in Trevi Therapeutics in the first quarter worth $47,000. Hsbc Holdings PLC acquired a new stake in Trevi Therapeutics in the second quarter worth $61,000. Finally, Rhumbline Advisers increased its position in Trevi Therapeutics by 44.8% in the second quarter. Rhumbline Advisers now owns 75,218 shares of the company's stock worth $224,000 after buying an additional 23,263 shares during the period. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.